PRE 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)
8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)
424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)
10-Q - 20/20 Biolabs, Inc. (0001139685) (Filer)
8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)
424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)
8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)
4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)
4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)
Fastest customizable press release news feed in the world
Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood ("MCED") test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services ("NDS"). NDS will provide ultrasound services and medical oversight in
Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory if called upon to support or augment testing by public health laboratories. Early in the COVID-19 pandemic, 20/20 Biolabs was among the first companies in the U.S. to import, validate, and dis
State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that management will attend the upcoming Sidoti Micro-Cap Virtual Conference. 20/20 BioLabs' Chief Executive Officer, Jonathan Cohen, will participate in one-on-one investor meetings and host a presentation from 3:15 PM ET to 3:45 PM ET in Track 1. Mr. Cohen will discuss the Company's recently reported quarterly results, recent partnership and licensing activity, and the plans to scale the OneTest platform. Sidoti Virtual Micr
Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs' AI-Enabled Multi-Cancer Early Detection Platform GAITHERSBURG, Md., May 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm developed by a team headed by James Hébert, Sc.D., Director of the South
Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia's National Practitioner Network WASHINGTON, Conn. and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases today announced that its OneTest™ for Cancer is now available through the Evexia Diagnostics platform, a leading marketplace that enables functional and integrative medicine practitioners to easily d
Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue Growth in Q2 and Full Year 2026 Recent Nasdaq Listing Under Ticker Symbol "AIDX" and New Growth Initiatives Position 20/20 BioLabs for 2026 Expansion GAITHERSBURG, Md., March 31, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the full year
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that 18 groups of Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Department of Health (MDH) to procure and administer the Company's patented OneTest™ multi-cancer early detection (MCED) blood test. The funding is from the state's Professional and Volunteer Firefighter
Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. ("20/20"), 20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc. ("ROKIT"), a global innovator in chronic disease prediction and regenerative health technologies. Under the agreement, 20/20 will integ
GAITHERSBURG, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. As population-scale cancer screening studies continue to generate trial data and real-world evidence, the medical community, co
Live finance-specific insights
State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March